Clinical Trial Update: LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial comparing afatinib to placebo for head and neck squamous cell cancer after chemo-radiotherapy was terminated with posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Head and Neck Neoplasms | Phase 3 | Status: TERMINATED | Results posted: 2019-03-01